- Galecto press release ( NASDAQ: GLTO ): Q2 GAAP EPS of -$0.67 beats by $0.02 .
- Cash, cash equivalents, and investments as of June 30, 2022 were approximately $85.9 million.
For further details see:
Galecto GAAP EPS of -$0.67 beats by $0.02For further details see:
Galecto GAAP EPS of -$0.67 beats by $0.02Market Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
BOSTON, May 01, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced that the first patient has been enrolled in an investigator-initiated Phase 2 trial to evaluate GB1...
Morgan Advanced Materials Plc (MCRUF) is expected to report for Q4 2023 Security Federal Corp (SFDL) is expected to report for Q1 2024 Bank of the James Financial Group Inc. (BOTJ) is expected to report for Q1 2024 OMV AG (OMVJF) is expected to report $1.91 for Q1 2024 Pola Orbis ...